Latest Breaking News On - That recognize additional - Page 1 : comparemela.com

Chemomab Therapeutics (CMMB) Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics (CMMB) Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Wadi morChemomab therapeutics ltdEuropean unionChemomab therapeuticsPatent officesThat recognize additionalChief executive officerChief scientific officerOrphan drug

Chemomab Awarded New Patents for CM-101, Its First-in Class Monoclonal Antibody in Clinical Development for Fibro-Inflammatory Diseases

Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. CM-101 i

Wadi morBarbara lindheimStrategic communicationsEuropean unionChemomab therapeutics ltdThat recognize additionalChief executive officerChief scientific officerOrphan drugLooking statementsPrivate securities litigation reformVice presidentPublic relationsChemomab therapeutics ltdUm 101Monoclonal antibody